TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05804370: Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Sponsor: NX Development Corp · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 170 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$984,060

Rescue Site Savings

+$656,040

Unlock Full NCT05804370 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05804370 Rescue Dossier →